Fred Hutch Cancer Center at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Fred Hutch Cancer Center brings 2 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2319. Its program centres on cell and gene therapy, from rebooting the immune system in severe autoimmune disease to viral vectors that deliver gene therapy to blood stem cells inside the body. It also covers myeloma, CLL and immune thrombocytopenia care.
| Organization | ASH 2026 Attendance |
|---|---|
Fred Hutch Cancer Center Seattle, WA | |
Independent nonprofit cancer research and treatment center in Seattle; Washington's only NCI-designated cancer center. | Booth Exhibiting at Booth 2319 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00am–10:00am Consensus or Controversy? Documenting And Discussing Investigators’ Approaches to the Management of Patients with Chronic Lymphocytic Leukemia How clinical investigators differ on managing chronic lymphocytic leukemia, comparing their answers on hard cases alongside current data and ongoing research. Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Symposium Fri Dec 11 3:00pm–6:00pm ITP at a Crossroads: Closing Knowledge Gaps in Pathophysiology, Treatment Selection, and Patient-Centred Care Personalizing immune thrombocytopenia care beyond platelet counts, weighing new therapies alongside fatigue, cognition, heavy periods, and quality of life. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Translating Evolving Standards of Care in Newly Diagnosed Multiple Myeloma Into Individualized Treatment Strategies Choosing four-drug starting regimens for newly diagnosed myeloma, using residual disease tests to guide therapy, and managing new side effects. Talk Viral Vector-Mediated In Vivo Hematopoietic Stem Cell Gene Therapy: Targets, Delivery, and Selection Delivering gene therapy to blood stem cells with viral vectors, plus surface marker edits that let corrected cells be enriched inside the body. |
Instantly find 20 buyers from Fred Hutch Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction